Previous 10 | Next 10 |
ACHC, ADUS, ANET, AWK, BCC, BRKR, BRX, BWXT, CCXI, CLR, COLM, EMN, EVER, FANG, FRPT, HLIT, HMN, KMT, LEG, MOS, NSP, NXPI, O, OGS, OHI, OTTR, PXD, RARE, REYN, RIG, RMBS, SANM, SBAC, SEDG, SPG, SYKE, TREX, TTWO, UCTT, UIS, UNVR, VNO, VNOM, VRNS, WMB, WWD, ZI For Seeking Alpha's full earnings se...
Biotech stock investing is full of ups and downs. Anyone who's been watching ChemoCentryx (NASDAQ: CCXI) and Deciphera Pharmaceuticals (NASDAQ: DCPH) lately can tell you all about the downs. Shares of ChemoCentryx were soaring in 2020 until an FDA advisory committee vote...
In my previous coverage, I said many analysts including myself thought a CRL was likely for avacopan. However, the FDA has accepted an amendment to the NDA and given an October 7 PDUFA date. There are reasons to think the outcome may be positive. For further details see: ...
Shares of the highly popular biotech stock ChemoCentryx (NASDAQ: CCXI) ticked up a few notches after a Wall Street analyst upgraded the stock to buy. Stifel analyst Dae Gon Ha thinks a recent development regarding the clinical-stage biotech's lead candidate is a pretty big deal that...
Baker Brothers’ 13F portfolio value decreased from $26.54B to $23.07B this quarter. The large stake in Alexion Pharmaceuticals was decreased during the quarter. The top three positions are Seagen, BeiGene, and Incyte Corporation and they add up to almost ~57% of the portfol...
naphtalina/iStock via Getty Images Jaguar Health rises on Street high target from Cantor Jaguar Health (JAGX) has risen ~15.4% in early trading after Cantor Fitzgerald began the coverage with an overweight rating. The Street-high target of $5.00 per share implies a premium of ~235.6...
ChemoCentryx (CCXI) jumps 15.3% premarket after filing an amendment to its New Drug Application ((NDA)) for avacopan for the treatment of Anti-neutrophil Cytoplasmic Autoantibody ((ANCA))-associated vasculitis, addressing points raised during the FDA Advisory Committee meeting on Ma...
SAN CARLOS, Calif., July 06, 2021 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc., (Nasdaq: CCXI), today announced that, following consultations with the U.S. Food and Drug Administration (FDA), it filed an amendment to its New Drug Application (NDA) for avacopan for the treatment of Anti-neutrophil...
Kessler Topaz Meltzer & Checker, LLP: Final Deadline Reminder for ChemoCentryx, Inc. Investors - CCXI Kessler Topaz Meltzer & Checker, LLP: Final Deadline Reminder for ChemoCentryx, Inc. Investors - CCXI PR Newswire RADNOR, Pa. , July 5, 2021 /PRNewsw...
Listen on the go! A daily podcast of Wall Street Breakfast will be available by 8:00 a.m. on Seeking Alpha, iTunes, Stitcher and Spotify. Economic reports in the week ahead U.S. markets are only open for four trading days after taking a breather for the Independence Day holiday. It is a quiet...
News, Short Squeeze, Breakout and More Instantly...
AMGEN SUCCESSFULLY COMPLETES ACQUISITION OF CHEMOCENTRYX PR Newswire TAVNEOS ® (avacopan), a First-in-Class Medicine for Patients With Severe Active ANCA-Associated Vasculitis, Added to Inflammation Portfolio THOUSAND OAKS, Calif. , Oct. 20, ...
-- Planned posters and an oral presentation will highlight data from the trials that supported the approval of TAVNEOS ® (avacopan) for patients with ANCA-associated vasculitis; additional poster will cover expression of kidney C5aR -- SAN CARLOS, Calif., Oct. 17,...
-- Two poster presentations planned for CCX559, including results from ongoing Phase I clinical study in patients with advanced solid tumors, and preclinical evidence from murine model -- SAN CARLOS, Calif., Oct. 05, 2022 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc., (Nasdaq: CCXI), tod...